Skip to main content
. 2021 Oct 6;8:740526. doi: 10.3389/fcvm.2021.740526

Figure 2.

Figure 2

LAPTM5 alleviates cardiomyocyte hypertrophy in vitro induced by Ang II. (A) Western blot analysis of LAPTM5 expression. (B) Representative images of cardiomyocytes infected with the indicated adenoviruses and then treated with PBS or Ang II for 48 h. (C) Quantitative results for the cell surface area of NRCMs infected with AdLAPTM5 or AdGFP (control) and treated with PBS or Ang II for 48 h. (D) The mRNA levels of ANP and β-MHC in each group (*P < 0.05 vs. AdGFP PBS, #P < 0.05 vs. AdGFP Ang II). (E) The protein levels of LAPTM5 detected by western blot. (F) Representative images of cardiomyocytes in the indicated groups. (G) Quantitative results for the cell surface area in the indicated groups. (H) The mRNA levels of ANP and β-MHC detected by real-time PCR in the indicated groups (*P < 0.05 vs. shRNA PBS, #P < 0.05 vs. shRNA Ang II).